Zopiclone 7.5 mg

DRUG3 trials

Sponsors

Utrecht Institute for Pharmaceutical Sciences, Eisai Inc., Idorsia Pharmaceuticals Ltd.

Conditions

HealthyHealthy ParticipantsInsomnia

Phase 1

Effects of Ramelteon on Driving Ability

CompletedNCT00319215

Utrecht Institute for Pharmaceutical SciencesInsomnia

Start: 2006-03-31End: 2006-07-31Target: 30Updated: 2007-04-25

Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects

CompletedNCT02583451

Eisai Inc.Healthy Participants

Start: 2015-11-30End: 2017-02-28Updated: 2018-09-06

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

CompletedNCT03892902

Idorsia Pharmaceuticals Ltd.Healthy

Start: 2019-03-25End: 2019-10-10Updated: 2019-10-31

Related Papers

Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials

Drugs & Aging2024-08-0910 citations

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

SLEEP2018-12-31225 citations

Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects.

2011-10-0178 citations